A retrospective analysis of hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis

Yuan,Meiqin; Wang,Zeng; Hu,Guinv; Yang,Yunshan; Lv,Wangxia; Lu,Fangxiao; Zhong,Haijun

doi:10.3892/mco.2016.918

A retrospective analysis of hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis

Authors:
- Meiqin Yuan
- Zeng Wang
- Guinv Hu
- Yunshan Yang
- Wangxia Lv
- Fangxiao Lu
- Haijun Zhong
View Affiliations

Affiliations: Department of Chemotherapy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China, Department of Surgical Oncology, Dongyang People's Hospital, Dongyang, Zhejiang 322100, P.R. China, Department of Radiology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang 310022, P.R. China
Published online on: June 2, 2016 https://doi.org/10.3892/mco.2016.918
Pages: 395-399

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peritoneal metastasis (PM) is a poor prognostic factor in patients with gastric cancer. The aim of this study was to evaluate the efficacy and safety of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced gastric cancer with PM by retrospective analysis. A total of 54 gastric cancer patients with positive ascitic fluid cytology were included in this study: 23 patients were treated with systemic chemotherapy combined with HIPEC (HIPEC+ group) and 31 received systemic chemotherapy alone (HIPEC‑ group). The patients were divided into 4 categories according to the changes of ascites, namely disappear, decrease, stable and increase. The disappear + decrease rate in the HIPEC+ group was 82.60%, which was statistically significantly superior to that of the HIPEC‑ group (54.80%). The disappear + decrease + stable rate was 95.70% in the HIPEC+ group and 74.20% in the HIPEC‑ group, but the difference was not statistically significant. In 33 patients with complete survival data, including 12 from the HIPEC+ and 21 from the HIPEC‑ group, the median progression‑free survival was 164 and 129 days, respectively, and the median overall survival (OS) was 494 and 223 days, respectively. In patients with ascites disappear/decrease/stable, the OS appeared to be better compared with that in patients with ascites increase, but the difference was not statistically significant. Further analysis revealed that patients with controlled disease (complete response + partial response + stable disease) may have a better OS compared with patients with progressive disease, with a statistically significant difference. The toxicities were well tolerated in both groups. Therefore, HIPEC was found to improve survival in advanced gastric cancer patients with PM, but the difference was not statistically significant, which may be attributed to the small number of cases. further studies with larger samples are required to confirm our data.

View Figures

View References

1	Brigand C, Arvieux C, Gilly FN and Glehen O: Treatment of peritoneal carcinomatosis in gastric cancers. Dig Dis. 22:366–373. 2004. View Article : Google Scholar : PubMed/NCBI
2	Isobe Y, Nashimoto A, Akazawa K, Oda I, Hayashi K, Miyashiro I, Katai H, Tsujitani S, Kodera Y, Seto Y and Kaminishi M: Gastric cancer treatment in Japan: 2008 annual report of the JGCA Nationwide Registry. Gastric Cancer. 14:301–316. 2011. View Article : Google Scholar : PubMed/NCBI
3	Yonemura Y, Endou Y, Sasaki T, Hirano M, Mizumoto A, Matsuda T, Takao N, Ichinose M, Miura M and Li Y: Surgical treatment for peritoneal carcinomatosis from gastric cancer. Eur J Surg Oncol. 36:1131–1138. 2010. View Article : Google Scholar : PubMed/NCBI
4	Kodera Y, Ito Y, Ito S, Ohashi N, Mochizuki Y, Yamamura Y, Koike M, Fujiwara M, Nakanishi H and Nakao A: Intraperitoneal paclitaxel: A possible impact of regional delivery for prevention of peritoneal carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology. 54:960–963. 2007.PubMed/NCBI
5	Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Hidemura A, Kaisaki S and Nagawa H: Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology. 76:311–314. 2009. View Article : Google Scholar : PubMed/NCBI
6	Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H and Nagawa H: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 21:67–70. 2010. View Article : Google Scholar : PubMed/NCBI
7	Ishigami H, Kitayama J, Kaisaki S, Yamaguchi H, Yamashita H, Emoto S and Nagawa H: Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis. Oncology. 79:269–272. 2010. View Article : Google Scholar : PubMed/NCBI
8	Matharu G, Tucker O and Alderson D: Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg. 98:1225–1235. 2011. View Article : Google Scholar : PubMed/NCBI
9	Yonemura Y, Ninomiya I, Kaji M, Sugiyama K, Fujimura T, Sawa T, Katayama K, Tanaka S, Hirono Y, Miwa K, et al: Prophylaxis with intraoperative chemohyperthermia against peritoneal recurrence of serosal invasion-positive gastric cancer. World J Surg. 19:450–454; discussion 455. 1995. View Article : Google Scholar : PubMed/NCBI
10	Dedrick RL: Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol. 12(3 Suppl 4): S1–S6. 1985.
11	Shimada T, Nomura M, Yokogawa K, Endo Y, Sasaki T, Miyamoto K and Yonemura Y: Pharmacokinetic advantage of intraperitoneal injection of docetaxel in the treatment for peritoneal dissemination of cancer in mice. J Pharm Pharmacol. 57:177–181. 2005. View Article : Google Scholar : PubMed/NCBI
12	Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW Jr and Myers CE: Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res. 41:1916–1922. 1981.PubMed/NCBI
13	Landry J, Tepper JE, Wood WC, Moulton EO, Koerner F and Sullinger J: Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys. 19:1357–1362. 1990. View Article : Google Scholar : PubMed/NCBI
14	Shiu MH and Fortner JG: Intraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats. Cancer Res. 40:4081–4084. 1980.PubMed/NCBI
15	Zhao C, Dai C and Chen X: Whole-body hyperthermia combined with hyperthermic intraperitoneal chemotherapy for the treatment of stage IV advanced gastric cancer. Int J Hyperthermia. 28:735–741. 2012. View Article : Google Scholar : PubMed/NCBI
16	Sun J, Song Y, Wang Z, Gao P, Chen X, Xu Y, Liang J and Xu H: Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: A meta-analysis of the randomized controlled trials. BMC Cancer. 12:5262012. View Article : Google Scholar : PubMed/NCBI
17	Esquivel J, Elias D, Baratti D, Kusamura S and Deraco M: Consensus statement on the loco regional treatment of colorectal cancer with peritoneal dissemination. J Surg Oncol. 98:263–267. 2008. View Article : Google Scholar : PubMed/NCBI
18	Portilla Gómez A: Peritoneal carcinomatosis. Ten years of applying the new combined triple therapy. Personal experience. Cir Esp. 82:346–351. 2007.(In Spanish). View Article : Google Scholar : PubMed/NCBI
19	Shimizu T and Saijo N: Common toxicity criteria: version 2.0, an improved reference for grading the adverse reaction of cancer treatment. Nihon Rinsho. 61:937–942. 2003.PubMed/NCBI
20	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
21	Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F and Howell SB: Intraperitoneal therapy for stage III ovarian cancer: A therapy whose time has come! J Clin Oncol. 20:3944–3946. 2002.PubMed/NCBI
22	Jaaback K, Johnson N and Lawrie TA: Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev CD005340. 2011. View Article : Google Scholar
23	Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H and Zoetmulder FA: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 21:3737–3743. 2003. View Article : Google Scholar : PubMed/NCBI
24	Sugarbaker PH: New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 7:69–76. 2006. View Article : Google Scholar : PubMed/NCBI
25	Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T, Isawa E, Sumida M and Ohkubo H: Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer. 79:884–891. 1997. View Article : Google Scholar : PubMed/NCBI
26	Beaujard AC, Glehen O, Caillot JL, Francois Y, Bienvenu J, Panteix G, Garbit F, Grandclément E, Vignal J and Gilly FN: Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer. 88:2512–2519. 2000. View Article : Google Scholar : PubMed/NCBI
27	Mussa A, Sandrucci S and Zanon C: Intraoperative chemohyperthermia for advanced gastric cancer: A new procedure with closed abdomen and previously constructed anastomosis. Tumori. 87(Suppl): S18–S20. 2001.PubMed/NCBI
28	Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T and Matsuki N: Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg. 92:370–375. 2005. View Article : Google Scholar : PubMed/NCBI
29	Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, Bereder JM, Lorimier G, Quenet F and Elias D: Association Française de Chirurgie: Peritoneal carcinomatosis from gastric cancer: A multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 17:2370–2377. 2010. View Article : Google Scholar : PubMed/NCBI
30	Yang XJ, Li Y and Yonemura Y: Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat gastric cancer with ascites and/or peritoneal carcinomatosis: Results from a Chinese center. J Surg Oncol. 101:457–464. 2010. View Article : Google Scholar : PubMed/NCBI
31	Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, Zhou YF, Xiong B, Yonemura Y and Li Y: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: Final results of a phase III randomized clinical trial. Ann Surg Oncol. 18:1575–1581. 2011. View Article : Google Scholar : PubMed/NCBI
32	Magge D, Zenati M, Mavanur A, Winer J, Ramalingam L, Jones H, Zureikat A, Holtzman M, Lee K, Ahrendt S, et al: Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol. 21:1448–1455. 2014. View Article : Google Scholar : PubMed/NCBI